Translational Psychiatry
October 31, 2025
Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al.
2 citations
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine's effects on...
International Journal of Advanced Research
October 31, 2025
Sagar Sanjeev Dua, Yasmine Busaibe, Eric Wang et al.
Background: Treatment-resistant depression (TRD) affects up to a third of patients with major depressive disorder and remains difficult to manage with conventional therapies. Rapid-acting antidepressants targeting the glutamatergic system, such as ketamine, esketamine, and dextromethorphan-bupropion, have emerged as promising alternatives. Nitrous oxide, also an NMDA receptor antagonist, has...
Translational Psychiatry
October 31, 2025
Giacomo D’andrea, Stefania Chiappini, Laura Ciavoni et al.
3 citations
BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...
Research Square
October 30, 2025
Elisabeth Kenne Sarenmalm, Salmir Nasic, Anna-Lena Emanuelsson Loft et al.
preprint
Abstract Purpose This 5-year longitudinal randomized controlled trial explored the long-term efficacy of a MBSR intervention for psychological and biological response in breast cancer survivors. Methods A total of 166 women were randomly assigned into one of 3 groups: MBSR, Active controls and non-MBSR. Data were collected at baseline, 3-months, 6-months and 1-year follow-up, thereafter yearly...
Journal of Psychiatric Research
October 30, 2025
Isabella S Ji, Morgan C H Cheng, Kayla M Teopiz et al.
2 citations
INTRODUCTION: Functional impairment is commonly reported amongst individuals with major depressive disorder (MDD) or treatment-resistant depression (TRD). Extant evidence suggests that ketamine and esketamine, N-methyl-D-aspartate (NMDA) receptor antagonists and glutamatergic modulators, have shown efficacy in treating MDD/TRD. While symptom reduction remains central to treatment, many...
Drug Design, Development and Therapy
October 29, 2025
Mengting Shen, Ye Xuan, Kaiyu Chen et al.
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on...
Figshare
October 29, 2025
Background Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability. Method We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May...
JMIR mHealth and uHealth
October 23, 2025
Walter Staiano, Christine E Callahan, Michelle Davis et al.
Anxiety and depressive disorders affect hundreds of millions globally, with substantial barriers limiting access to evidence-based treatments like cognitive behavioral therapy. Digital mental health interventions offer potential solutions to improve access to support. However, evidence of efficacy through randomized controlled trials is essential for clinical adoption. This study evaluated the...
MedScien
October 23, 2025
Ziteng Qiu
More than 280 million individuals worldwide suffer from depression, which is one of the main causes of mental disability. It has multiple subtypes, and conventional treatments have limitations such as slow onset of action, high non-response rate, and numerous side effects. For instance, it takes two to six weeks for selective serotonin reuptake inhibitors (SSRIs) to start working, and about 30%...
Hospital Pharmacy
October 23, 2025
Moomal Memon, Rukhsana Gul, Arif Gul et al.
1 citation
Depression, projected to be the leading cause of global disability by 2030, affects up to 19.62% of Pakistan's population. Treatment-resistant depression (TRD), characterized by poor response to at least two antidepressants, poses a major clinical challenge. Although interventions like ECT exist, their use is limited by systemic barriers. Esketamine, an NMDA receptor antagonist, offers a...